MedPath

Isosorbide mononitrate

Generic Name
Isosorbide mononitrate
Brand Names
Imdur, Ismo, Monoket
Drug Type
Small Molecule
Chemical Formula
C6H9NO6
CAS Number
16051-77-7
Unique Ingredient Identifier
LX1OH63030
Background

Isosorbide mononitrate is an organic nitrate with vasodilating properties. It is an anti-anginal agent that works by relaxing the smooth muscles of both arteries and veins, but but predominantly veins to reduce cardiac preload. Isosorbide mononitrate is an active metabolite of isosorbide dinitrate. Like other organic nitrates, isosorbide mononitrate acts as a prodrug for its active metabolite, nitric oxide, which mediates the therapeutic action of isosorbide mononitrate. Isosorbide mononitrate has a longer duration of action than nitroglycerin due to its slow onset of absorption and metabolism.

First approved by the FDA in 1991, isosorbide mononitrate is used for the prevention and management of angina pectoris caused by coronary artery disease; however, the onset of action of orally-administered isosorbide mononitrate is not rapid enough to offset an acute anginal episode. It is available in oral tablets generically and under the brand name ISMO and Monoket. The extended-release forms of the drug are also available generically and under the brand name Imdur.

Indication

Isosorbide mononitrate is indicated for the prevention and management of angina pectoris due to coronary artery disease. The onset of action of oral isosorbide mononitrate is not sufficiently rapid to be useful in aborting an acute anginal episode.

Associated Conditions
Angina Pectoris

Nitrate's Effect on Activity Tolerance in Heart Failure With Preserved Ejection Fraction

Phase 2
Completed
Conditions
Heart Failure
Interventions
First Posted Date
2014-02-03
Last Posted Date
2016-11-28
Lead Sponsor
Adrian Hernandez
Target Recruit Count
110
Registration Number
NCT02053493
Locations
🇺🇸

Lancaster General Hospital, Lancaster, Pennsylvania, United States

🇺🇸

University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States

🇺🇸

Tufts Medical Center, Boston, Massachusetts, United States

and more 19 locations

The Effects of Antihypertensive Agents on Central Blood Pressure in Healthy Participants and Participants With Hypertension (MK-0000-166) (COMPLETED)

Phase 1
Completed
Conditions
Hypertension
Interventions
Drug: Placebo
First Posted Date
2010-05-25
Last Posted Date
2015-10-09
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
38
Registration Number
NCT01130168

Secondary Prophylaxis After Variceal Bleeding in Non-Responders

Phase 4
Completed
Conditions
Gastrointestinal Hemorrhage
Portal Hypertension
Cirrhosis
First Posted Date
2007-03-21
Last Posted Date
2007-03-21
Lead Sponsor
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Target Recruit Count
50
Registration Number
NCT00450164
Locations
🇪🇸

Unidad de Sangrantes, HSCSP, Barcelona, Spain

© Copyright 2025. All Rights Reserved by MedPath